TotalMarketCap

Passage BIO

PASGNasdaq United StatesHealth CareBiotechnology: Biological Products (No Diagnostic Substances)

Market cap

$11.053 M

$3.44 -1.01%

Close of 6 Nov 2026

As of 6 Nov 2026, Passage BIO (PASG) has a market capitalization of $11.1M. Market cap measures the value of outstanding equity at market prices; company totals combine applicable share classes. Prices and market caps come from Nasdaq, with financial fundamentals from SEC filings. See sources and calculation details.

Revenue

—

Not reported

Earnings

-$45.5M

Loss-making

Shares outstanding

3,217,810

Latest filing cover page

P/E ratio

—

Cap ÷ net income

Biotechnology: Biological Products (No Diagnostic Substances), ranked by market cap

All 163 →
  1. #147BioCardiaBCDA$13.4M
  2. #148TScan TherapeuticsTCRX$11.5M
  3. #149Passage BIOPASG$11.1M
  4. #150Intensity TherapeuticsINTS$10.2M
  5. #151In8bioINAB$8.30M

What if Passage BIO were worth as much as…

Open the what-if tool →

Gold $28.2T

$8,775,184

Per share 2,554,639× higher

Bitcoin $1.53T

$474,809.92

Per share 138,227× higher

Apple $5.02T

$1,558,757

Per share 453,787× higher

Or at a round number

$20.0M$50.0M$100.0M$200.0M

Where these numbers come from

Share counts and financials for Passage BIO are taken from its own SEC filings via EDGAR: public record, not an estimate. Market cap is shares outstanding multiplied by the latest close. Read the methodology.